Sage’s dalzanemdor miss in Alzheimer’s trial

Sage Therapeutics’ (Nasdaq: SAGE) share price fell 11% to $6 in pre-market activity on Tuesday, after it announced disappointing top-line results from LIGHTWAVE, a 12-week, Phase II randomized, double-blind, placebo-controlled study to evaluate the effects of dalzanemdor (SAGE-718) in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (AD).

Cambridge, USA-based Sage noted that the LIGHTWAVE Study did not demonstrate a statistically-significant difference from baseline in participants treated with dalzanemdor versus placebo on the Wechsler Adult Intelligence Scale Fourth Edition (WAIS-IV) Coding Test score at Day 84, the primary outcome measure of the study.

Will drop development in AD